Theravance Biopharma Inc (TBPH):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C9855)
◆英語タイトル:Theravance Biopharma Inc (TBPH) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9855
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年11月
◆ページ数:60
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥26,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥53,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥80,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Theravance Biopharma Inc (Theravance Biopharma) is a diversified biopharmaceutical company. Its flagship product, Vibativ (telavancin) is a bactericidal, once-daily injectable antibiotic to treat patients with serious, life-threatening infections due to Staphylococcus aureus and other Gram-positive bacteria, including methicillin-resistant (MRSA) strains. Its major pipeline programs targeted towards the treatment of chronic obstructive pulmonary disease (COPD); asthma; neurogenic orthostatic hypotension (nOH); opioid-induced constipation (OIC); hepatitis C virus; gastrointestinal motility disorders; ulcerative colitis; heart failure; chronic kidney disease (CKD); Crohn’s disease; gastroparesis; concurrent bacteremia; rheumatoid arthritis; and myelofibrosis and blood pressure. The company has subsidiaries in the US, Ireland and the UK. Theravance is headquartered in George Town, Cayman Islands, the UK.

Theravance Biopharma Inc (TBPH) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Theravance Biopharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Janssen Biotech Enters into Co-Development Agreement with Theravance Biopharma Ireland 11
Theravance Biopharma Enters into Development and Commercialization Agreement with Mylan 12
Licensing Agreements 13
Takeda Pharma Enters into Licensing Agreement with Theravance Biopharma for TD-8954 13
Trek Therapeutics Enters into Licensing Agreement with Theravance Biopharma 14
Theravance Biopharma Enters into Co-Development Agreement with SciClone Pharma 15
Equity Offering 16
Theravance Biopharma Raises USD100 Million in Public Offering of Shares 16
Theravance Biopharma Raises USD115 Million in Public Offering of Shares 18
Theravance Biopharma Raises USD23 Million in Private Placement of Shares 20
Theravance Biopharma Raises USD55 Million in Private Placement of Shares 21
Debt Offering 23
Theravance Biopharma Raises USD230 Million in Public Offering of 3.25% Notes Due 2023 23
Asset Transactions 25
Cumberland Pharma to Acquire Vibative from Theravance Biopharma 25
Theravance Biopharma Inc – Key Competitors 26
Theravance Biopharma Inc – Key Employees 27
Theravance Biopharma Inc – Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Recent Developments 29
Financial Announcements 29
Nov 06, 2018: Theravance Biopharma reports third quarter 2018 financial results and provides business update 29
Aug 01, 2018: Theravance Biopharma reports second quarter 2018 financial results and provides business update 31
May 08, 2018: Theravance Biopharma Reports First Quarter 2018 Financial Results and Provides Business Update 33
Feb 27, 2018: Theravance Biopharma Announces Fourth Quarter and Full Year 2017 Financial Results 35
Nov 07, 2017: Theravance Biopharma Reports Third Quarter 2017 Financial Results and Provides Business Update 37
Aug 08, 2017: Theravance Biopharma Reports Second Quarter 2017 Financial Results and Provides Business Update 39
May 09, 2017: Theravance Biopharma Reports First Quarter 2017 Financial Results and Provides Business Update 41
Feb 27, 2017: Theravance Biopharma Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update 43
Corporate Communications 45
Jul 31, 2017: Theravance Biopharma Appoints Shehnaaz Suliman, MD, as Senior Vice President of Corporate Development and Strategy 45
Product News 46
05/17/2017: Theravance Biopharma and Mylan to Present Additional Data for Revefenacin (TD-4208) in Several Presentations at 2017 ATS 46
01/29/2018: Theravance Biopharma and Mylan Announce FDA Acceptance of New Drug Application for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease 47
01/23/2017: Theravance Biopharma Reports New Data from Ongoing TOUR Observational Patient Registry in Oral Presentation at SCCM Critical Care Congress 48
01/17/2017: Theravance Biopharma to Present New Data from Ongoing TOUR Observational Patient Registry at SCCM Critical Care Congress 50
Product Approvals 51
Nov 13, 2017: Theravance Biopharma and Mylan Submit New Drug Application to FDA for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease 51
Clinical Trials 52
Nov 01, 2017: Theravance Biopharma and Mylan Report Additional Positive Phase 3 Data for Revefenacin (TD-4208) in Multiple Presentations at 2017 CHEST Annual Meeting 52
Oct 24, 2017: Theravance Biopharma to Present New Data on Revefenacin (TD-4208) at 2017 CHEST Annual Meeting 54
Jul 19, 2017: Theravance Biopharma and Mylan Announce Positive Results from 12-Month Phase 3 Safety Study of Revefenacin (TD-4208) in Patients with Chronic Obstructive Pulmonary Disease (COPD) 55
May 23, 2017: Theravance Biopharma and Mylan Report Additional Phase 3 Data for Revefenacin (TD-4208) in Several Presentations at 2017 ATS 56
Feb 17, 2017: Theravance Biopharma Presents Positive Clinical Data on TD-1473 at the 12th Congress of the European Crohn’s and Colitis Organization 58
Feb 13, 2017: Theravance Biopharma to Present Clinical Data on TD-1473 at the 12th Congress of the European Crohn’s and Colitis Organization 59
Appendix 60
Methodology 60
About GlobalData 60
Contact Us 60
Disclaimer 60

List of Tables
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Theravance Biopharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Theravance Biopharma Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Janssen Biotech Enters into Co-Development Agreement with Theravance Biopharma Ireland 11
Theravance Biopharma Enters into Development and Commercialization Agreement with Mylan 12
Takeda Pharma Enters into Licensing Agreement with Theravance Biopharma for TD-8954 13
Trek Therapeutics Enters into Licensing Agreement with Theravance Biopharma 14
Theravance Biopharma Enters into Co-Development Agreement with SciClone Pharma 15
Theravance Biopharma Raises USD100 Million in Public Offering of Shares 16
Theravance Biopharma Raises USD115 Million in Public Offering of Shares 18
Theravance Biopharma Raises USD23 Million in Private Placement of Shares 20
Theravance Biopharma Raises USD55 Million in Private Placement of Shares 21
Theravance Biopharma Raises USD230 Million in Public Offering of 3.25% Notes Due 2023 23
Cumberland Pharma to Acquire Vibative from Theravance Biopharma 25
Theravance Biopharma Inc, Key Competitors 26
Theravance Biopharma Inc, Key Employees 27
Theravance Biopharma Inc, Subsidiaries 28

List of Figures
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Theravance Biopharma Inc (TBPH):製薬・医療:M&Aディール及び事業提携情報(Theravance Biopharma Inc (TBPH) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆